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clinical snippets
Understanding Psoriasis Treatment
The fumaric acid ester dimethyl fumarate 
(DMF) and its metabolites have been used 
for some 50 years to treat psoriasis, the fea-
tures of which include angiogenesis-related 
pathology. García-Caballero and colleagues 
found that DMF inhibits the differentiation, 
proliferation, and migration of endothelial 
cells in vitro in a dose-dependent fash-
ion. Chick chorioallantoic membrane and 
zebrafish embryo neovascularization assays 
revealed that DMF inhibited in vivo angiogenesis. This function of DMF may explain 
the previously reported antipsoriatic, antitumoral, and antimetastatic activities of this 
compound. Furthermore, the results suggest that DMF may be a useful therapy for 
angiogenesis-related malignancies. See page 1347
Enlightening Therapy
The vitiligo-inducing compound mono-
benzone induces a robust antimelanoma 
immunity involving a CD8+ T-cell response. 
In studies to address the mechanism of 
this action, van den Boorn and colleagues 
demonstrated that monobenzone inactivated 
the tyrosinase pigment-synthesis enzyme. 
In addition, monobenzone exposure 
generated quinine-haptens, melanosome 
autophagy, and secretion of melanocyte 
antigen–containing exosomes in response to 
induced reactive oxygen species. Moreover, 
this monobenzone treatment activated dendritic cells and resulted in a strong T-cell 
immunity against the melanoma cells. This potent immune response against pigmented 
cells offers an opportunity in the field of cancer immunotherapy. See page 1240
Barrier Protein Alterations
Tumor necrosis factor (TNF)-α overexpression and epi-
dermal barrier deficiency have both been implicated 
in the pathogenesis of psoriasis. Kim and colleagues 
observed that expression of the epidermal barrier 
proteins filaggrin and loricrin was decreased in lesional 
and nonlesional skin of psoriasis patients as well as in 
primary human keratinocytes treated with TNF-α and 
that these alterations occurred via a c-Jun N-terminal 
kinase–dependent pathway. Importantly, patients 
treated with the TNF-α antagonist etanercept exhibited 
increased expression of filaggrin and loricrin in concert 
with clinical disease improvement. These data indicate 
that barrier protein deficiency in psoriasis patients may 
be acquired through TNF-α-mediated downregulation. 
See page 1272
Flavonoids in the Diet
Fisetin, a naturally occurring 
flavonol with neuroprotective 
and anticancer properties, was 
shown to decrease the viability 
of human melanoma cells 
via G1 cell cycle arrest. These 
antiproliferative effects resulted 
from interference with key 
elements of the Wnt/ b-catenin 
signaling pathway, which has 
previously been shown to 
be activated constitutively in 
malignant cancers, including 
melanoma. Inhibition of growth 
of xenografted melanomas 
and decreased expression of 
the Wnt downstream target 
microphthalmia-associated 
transcription factor were 
observed in mice treated with 
fisetin. These findings provide 
strong evidence that fisetin may 
be used as a chemopreventive or 
therapeutic compound against 
melanoma. See page 1291
Differential 
Degradation
Modulation of skin pigmentation 
occurs via interruption of melanin 
biosynthesis or inhibition of 
melanosome transfer from 
melanocytes to keratinocytes. 
The mechanism of melanosome 
processing after transfer via 
melanosomal degradation is 
a topic of interest. Ebanks and 
colleagues developed a novel 
system involving fluorescent 
labeling of melanosomes and 
subsequent analysis using 
transmission electron microscopy, 
indirect immunofluorescence 
with confocal microscopy, 
and flow cytometry. As 
compared with keratinocytes 
from dark skin, keratinocytes 
from light skin consistently 
exhibited a higher rate of 
melanosomal loss, suggesting 
that differential pigment 
degradation occurs in different 
skin types. See page 1226
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